Drug Fails to Help Kidney Transplant Recipients
Embargo expired: 1/10/2013 5:00 PM EST
Source Newsroom: American Society of Nephrology (ASN)
Results come from large, randomized, placebo-controlled trial
• While safe and well-tolerated, angiotensin II blockade did not lessen tissue scarring or prevent kidney failure in kidney transplant recipients.
Angiotensin II blockade is known to slow kidney disease progression in individuals without transplants.
Newswise — Washington, DC (January 10, 2013) — A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Immunosuppressants help prolong the function of transplanted organs, but therapies that target non-immunological damage to these organs—such as elevated blood pressure and tissue scarring (or fibrosis)—have not been studied.
Angiotensin II blockade, which causes blood vessels to dilate, can slow the progression of kidney disease in individuals without kidney transplants. Hassan Ibrahim, MD (University of Minnesota) and his colleagues set out to test the strategy in transplant recipients. “To our knowledge this is the first randomized placebo-controlled trial of angiotensin II blockade in these patients,” said Dr. Ibrahim.
The investigators assigned 153 kidney transplant recipients to receive the angiotensin II receptor blocker losartan or placebo within three months of transplantation, continuing treatment for five years.
“Contrary to what has been observed in native kidney disease, angiotensin II blockade did not demonstrate a statistically significant benefit in lessening fibrosis or terminal kidney failure from severe fibrosis. Nevertheless, angiotensin II blockade was safe and well-tolerated,” said Dr. Ibrahim. He noted that a similar trial is ongoing in Canada.
The findings provide valuable information for future studies of non-immunological therapies for kidney transplant recipients.
Study co-authors include Scott Jackson, MS, Jeffrey Connaire, MD, Arthur Matas, MD, Arthur Ney, MD, Ann West, RN, Nicole Lentsch, RN, Jensina Ericksen, Jenny Bodner, RN, Bertram Kasiske, MD, FACP (Hennepin County Medical Center); Behzad Najafian, MD (University of Washington); and Michael Mauer, MD (University of Minnesota).
Disclosures: The study was sponsored by NIDDK (grant #U01 DK060706-09). The drug and placebo were provided by Merck Pharmaceuticals.
The article, entitled “Angiotensin II Blockade in Kidney Transplant Recipients,” will appear online at http://jasn.asnjournals.org/ on January 10, 2013, doi: 10.1681/2012080777.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #